It is time to end our love affair with short-acting β2-agonists in asthma
- PMID: 36267894
- PMCID: PMC9574554
- DOI: 10.1183/23120541.00353-2022
It is time to end our love affair with short-acting β2-agonists in asthma
Abstract
In this issue of ERJOR, Noorduynet al. add data to the growing literature showing that SABA overuse in asthma is both common and associated with severe exacerbations. It is time to take note and act to tackle this global issue. https://bit.ly/3BfwhfS.
Copyright ©The authors 2022.
Conflict of interest statement
Conflict of interest: M.G. Crooks has received speaker fees and/or nonfinancial support from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis and Pfizer; has sat on advisory boards for AstraZeneca and Chiesi; and has received grants from AstraZeneca, Boehringer Ingelheim, Chiesi and Pfizer. Conflict of interest: S. Faruqi has received speaker fees from AstraZeneca, GSK, Chiesi and Novartis.
References
-
- GBD 2015 Chronic Respiratory Disease Collaborators . Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med 2017; 5: 691–706. doi:10.1016/S2213-2600(17)30293-X - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources